{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:44:41Z","timestamp":1789753481817,"version":"4.0.1"},"reference-count":33,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Introduction: The objective of this study was to compare the continuous infusion of cefepime with the intermittent infusion in patients with sepsis caused by Gram-negative bacilli (GNB). Methods: Randomized 1:1 multicenter double-blinded placebo-controlled study with allocation concealment; multicenter study in the intensive care units of Colombia. Patients with sepsis, severe sepsis or septic shock, and GNB-suspected bacteremia. Cefepime was administered for 7 to 14 days over 30 m intermittently every 8 h over 24 h plus continuous saline solution (0.9%) (G1) or 3 g administered continuously plus saline solution every 8 h (0.9%) (G2). The percentage of clinical response at 3, 7, and 14 days, relapse at 28 days, and mortality at discharge were measured. Results: The recruitment was stopped at the suggestion of the Institutional Review Board (IRB) following an FDA alert about cefepime. Thirty-two patients were randomized; 25 received the intervention, and GNB bacteremia was confirmed in 16 (9 G1 and 7 G2). Favorable clinical response in days 3, 7, and 14 was 88.8%, 88.8%, and 77.8% (G1) and was similar for G2 (85.7%). There were no relapses or deaths in G2, while in G1, one relapse and two deaths were observed. Conclusions: The results of this study support the use of cefepime for the treatment of Gram-negative infections in critically ill patients, but we could not demonstrate differences between continuous or intermittent administration because of the small sample size, given the early suspension of the study.<\/jats:p>","DOI":"10.3390\/antibiotics13030229","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T05:59:19Z","timestamp":1709186359000},"page":"229","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy of Continuous vs. Intermittent Administration of Cefepime in Adult ICU Patients with Gram-Negative Bacilli Bacteremia: A Randomized Double-Blind Clinical Study"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5419-4494","authenticated-orcid":false,"given":"Carlos Arturo","family":"\u00c1lvarez-Moreno","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Infectious Diseases, Universidad Nacional de Colombia, Bogot\u00e1 111321, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Cristina","family":"Nocua-B\u00e1ez","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Infectious Diseases, Universidad Nacional de Colombia, Bogot\u00e1 111321, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3374-5709","authenticated-orcid":false,"given":"Guillermo","family":"Ortiz","sequence":"additional","affiliation":[{"name":"Santa Clara Hospital, Bogot\u00e1 111711, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Torres","sequence":"additional","affiliation":[{"name":"Pablo Tob\u00f3n Uribe Hospital, Medell\u00edn 050034, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Montenegro","sequence":"additional","affiliation":[{"name":"Palermo Clinic, Bogot\u00e1 111311, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Williams","family":"Cervera","sequence":"additional","affiliation":[{"name":"San Ignacio University Hospital, Bogot\u00e1 110231, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Fernando","family":"Zuluaga","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Nueva El Lago, Bogot\u00e1 110221, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alonso","family":"G\u00f3mez","sequence":"additional","affiliation":[{"name":"Palermo Clinic, Bogot\u00e1 111311, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13054-019-2378-9","article-title":"Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Soci\u00e9t\u00e9 Fran\u00e7aise de Pharmacologie et Th\u00e9rapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Anesth\u00e9sie et R\u00e9animation-SFAR)","volume":"23","author":"Guilhaumou","year":"2019","journal-title":"Crit. Care"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.12998\/wjcc.v10.i6.1795","article-title":"Multidrug-resistant organisms in intensive care units and logistic analysis of risk factors","volume":"10","author":"Han","year":"2022","journal-title":"World J. Clin. Cases"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2165\/00003495-199447030-00007","article-title":"Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use","volume":"47","author":"Barradell","year":"1994","journal-title":"Drugs"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s40262-022-01137-y","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Cefepime","volume":"61","author":"Pais","year":"2022","journal-title":"Clin. Pharmacokinet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of Adults with Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1700582","DOI":"10.1183\/13993003.00582-2017","article-title":"International ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)\/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociaci\u00f3n Latinoamericana del T\u00f3rax (ALAT)","volume":"50","author":"Torres","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ijantimicag.2006.08.031","article-title":"Cefepime versus ceftazidime: Considerations for empirical use in critically ill patients","volume":"29","author":"Roberts","year":"2007","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1385\/MO:19:3:161","article-title":"Cefepime monotherapy as an empirical initial treatment of patients with febrile neutropenia","volume":"19","author":"Montalar","year":"2002","journal-title":"Med. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JOP.18.00269","article-title":"Optimal Management of Neutropenic Fever in Patients with Cancer","volume":"15","author":"Zimmer","year":"2019","journal-title":"J. Oncol. Pract."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0149-2918(00)87978-3","article-title":"Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion","volume":"22","author":"Burgess","year":"2000","journal-title":"Clin Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-200666010-00001","article-title":"Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: Impact on the development of resistance","volume":"66","author":"DeRyke","year":"2006","journal-title":"Drugs"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.2165\/00003495-200565170-00006","article-title":"Continuous versus intermittent intravenous administration of antibacterials with time-dependent action: A systematic review of pharmacokinetic and pharmacodynamic parameters","volume":"65","author":"Kasiakou","year":"2005","journal-title":"Drugs"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"360","DOI":"10.5414\/CPP43360","article-title":"Cefepime in critically ill patients: Continuous infusion vs. an intermittent dosing regimen","volume":"43","author":"Georges","year":"2005","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","article-title":"APACHE II: A severity of disease classification system","volume":"13","author":"Knaus","year":"1985","journal-title":"Crit. Care Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/BF01709751","article-title":"The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine","volume":"22","author":"Vincent","year":"1996","journal-title":"Intensive Care Med."},{"key":"ref_16","unstructured":"US Food and Drug Administration (2008, February 25). Early Communication about an Ongoing Safety Review Cefepime (Marketed as Maxipime), Available online: http:\/\/www.fda.gov\/Cder\/Drug\/early_comm\/cefepime.htm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1473-3099(07)70109-3","article-title":"Efficacy and safety of cefepime: A systematic review and meta-analysis","volume":"7","author":"Yahav","year":"2007","journal-title":"Lancet Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/655131","article-title":"Meta-analysis of a possible signal of increased mortality associated with cefepime use","volume":"51","author":"Kim","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"P093","DOI":"10.1186\/cc1160","article-title":"Cefepime in critically ill patients: Continuous infusion versus intermittent regimen","volume":"5","author":"Georges","year":"2001","journal-title":"Crit. Care"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/jac\/dkl478","article-title":"Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study","volume":"59","author":"Roberts","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1365-2125.2006.02730.x","article-title":"Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: Pharmacokinetics\/pharmacodynamics, bacterial susceptibility and clinical efficacy","volume":"63","author":"Oudijk","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1128\/AAC.00329-06","article-title":"Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection","volume":"50","author":"Lau","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"R51","DOI":"10.1186\/cc8941","article-title":"Prospective monitoring of cefepime in intensive care unit adult patients","volume":"14","author":"Chapuis","year":"2010","journal-title":"Crit. Care"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/phar.2332","article-title":"Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Prospective, Open-Label Study","volume":"39","author":"Philpott","year":"2019","journal-title":"Pharmacotherapy"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Jean-Michel, V., Homey, C., Devos, P., Delannoy, P.-Y., Boussekey, N., Caulier, T., Leroy, O., and Georges, H. (2022). Continuous Infusion of High Doses of Cefepime in Intensive Care Unit: Assessment of Steady-State Plasma Level and Incidence on Neurotoxicity. Antibiotics, 12.","DOI":"10.3390\/antibiotics12010069"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1211\/002235702171","article-title":"Continuous infusion versus intermittent administration of cefepime in patients with Gram-negative bacilli bacteraemia","volume":"54","author":"Jaruratanasirikul","year":"2002","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1128\/AAC.02365-12","article-title":"Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections","volume":"57","author":"Bauer","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1086\/510590","article-title":"Piperacillin-tazobactam for Pseudomonas aeruginosa infection: Clinical implications of an extended-infusion dosing strategy","volume":"44","author":"Lodise","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_29","unstructured":"P\u00e9rez, A., Rodr\u00edguez, N., Gil, G.F.A., and Ram\u00edrez, G. (2001). Tama\u00f1o de la muestra. Un Programa Sistematizado Para Estimar el Tama\u00f1o de la Muestra Requerido Para Dise\u00f1os de Investigaci\u00f3n. V 1.1, Pontifica Universidad Javeriana."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0924-8579(01)00329-6","article-title":"Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia","volume":"17","author":"Nicolau","year":"2001","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1097\/00003246-199510000-00007","article-title":"Multiple organ dysfunction score: A reliable descriptor of a complex clinical outcome","volume":"23","author":"Marshall","year":"1995","journal-title":"Crit. Care Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1097\/01.CCM.0000050454.01978.3B","article-title":"2001 SCCM\/ESICM\/ACCP\/ATS\/SIS International Sepsis Definitions Conference","volume":"31","author":"Levy","year":"2003","journal-title":"Crit. Care Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1097\/01.CCM.0000168253.91200.83","article-title":"The international sepsis forum consensus conference on definitions of infection in the intensive care unit","volume":"33","author":"Calandra","year":"2005","journal-title":"Crit. Care Med."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/3\/229\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:07:07Z","timestamp":1760105227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/3\/229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":33,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["antibiotics13030229"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics13030229","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,29]]}}}